News Releases

2022-08/29
NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421
1
2022-08/02
United BioPharma announces JCI publication of UB-221 mAb data demonstrating unique profiles of potent IgE neutralization, IgE synthesis reduction, and durable urticaria symptom relief
2
2022-05/26
United BioPharma Receives IND Approval from TFDA for A Phase 2 Study of UB-221 in Adults with Chronic Spontaneous Urticaria
3
2021-10/18
United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621
4
2021-08/18
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure
5
2021-07/15
United BioPharma Received IND Approval from China NMPA for a larger Phase 2 Trial with multi-dosing UB-621 to demonstrate optimal clinical efficacy in treatment of Recurrent Genital Herpes
6
2020-12/10
United BioPharma won the “2020 National Talent Development Award''
7
2020-11/11
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
8
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
9
2022-08/29
NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421
1
2022-08/02
United BioPharma announces JCI publication of UB-221 mAb data demonstrating unique profiles of potent IgE neutralization, IgE synthesis reduction, and durable urticaria symptom relief
2
2022-05/26
United BioPharma Receives IND Approval from TFDA for A Phase 2 Study of UB-221 in Adults with Chronic Spontaneous Urticaria
3
2021-10/18
United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621
4
2021-08/18
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure
5
2021-07/15
United BioPharma Received IND Approval from China NMPA for a larger Phase 2 Trial with multi-dosing UB-621 to demonstrate optimal clinical efficacy in treatment of Recurrent Genital Herpes
6
2020-12/10
United BioPharma won the “2020 National Talent Development Award''
7
2020-11/11
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
8
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
9
President Dr. Mei-June Liao received the recognition for “Bioprocessing Executive of the year” at the 2017 Asia-Pacific Bioprocessing Excellence Forum 2017-02/24
The phase II data of UB-421 was presented at the late breaker session at CROI 2017 2017-02/15
Filed IND for UB-421 phase III clinical trial (HAART substitution) to TFDA 2017-01/15
Received certificate of occupancy for UBP’s eight-story (7000 sq Meter) headquarter building based in Huko, Hsinchu county designed for administrative, R&D and large scale protein drug manufacturing activities 2016-12/15
Filed IND for UB-921 (Anti-HER2 monoclonal antibody) phase I clinical trial to TFDA 2016-12/15
UBP entered into a licensing agreement with UBI US Holdings LLC and UBI IP Holdings, the subsidiary of United Biomedical, Inc (UBI) for exclusive US and ROW (ex-Asia) rights for development and commercialization of UB-421 2016-08/15
UB-421 for HIV treatment won the 12th National Innovation Prize given by Taiwan Biotechnology Strategic Planning Association 2015-12/15
IND submission of a phase I clinical trial for UB-621, an Anti-HSV-gD antibody, was approved by Taiwan Food and Drug Administration (TFDA) 2015-11/15
United BioPharma received approval for UB-421 Phase II clinical trial for HAART substitution treatment in treatment stabilized HIV patients from Taiwan Food and Drug Administration (TFDA) 2015-06/15
Filed an IND submission of a phase II clinical trial for HAART substitution therapy in treatment stabilized HIV patients with Taiwan Food and Drug Administration (TFDA) 2015-02/15
United BioPharma, Inc. Copyright (c) 2023